The study of Prediction of progression of DMG and DSG using MRI-FBPA PET

The prospective study of progression of diffuse midline glioma and deep seated glioma using MRI-FBPA PET fusion images - MRI-PET Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs032230489

Enrollment

Registered

2023-12-04

Start date

2024-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse midline glioma,Deep seated glioma

Interventions

The properties of 18F-BPA PET about the prediction of progression of DMG or DSG lesions at pretreatment status Multi-institutional joint research

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diffuse Midline Glioma patients showing T2WI high intensity lesions in hypothalamus or Thalamus or Brain stem or spinal cord Deep Seated Glioma patients Diagnosed as Glioma preoperatively together with Gadolinium ring-like enhanced lesions on pretreatment MRI Age :16 y.o. over and 75 y.o. under Within 6 weeks after tumor biopsy or tumor partial removal (If surgery was done) Completion of initial treatment including surgery, chemotherapy and/or radiation therapy Perfotmance status socore 3 under by ECOG criteria Labo data within 2 months showing Neutrophil 1,500/mm3 over Hemoglobin 8.0 g/dL over Platelets 10x10^4/mm3 over AST(GOT) 120 IU/L under ALT(GPT) 120 IU/L under eGFR 45 mL/min/1.73m2 over

Exclusion criteria

Exclusion criteria: DSG patients showing IDH mutant on surgical specimens WHO grade 2 or grade 1 or pathologically diagnosed as inflammation or demyelination disease previous chemotherapy or previous radiation therapy CSF dissemination including ventricle or cerebellum or brain stem or spinal cord active cancer lesions active cardiac disease phenylketonuria pregnant or during breast feeding Given other trial drugs within 3 months HIV antibody positive HBs antigen positive Inappropriate judged by our doctors

Design outcomes

Primary

Measure	Time frame
Prediction rate of progression of DMG or DSG using 18F-BPA PET high uptake lesion	—

Secondary

Measure	Time frame
Overall Survival Progression free survival The status of H3K27-altered in Immunohistochemical staining of the surgical specimens RIng-like enhancement or T2WI high intensity lesions The maximal diameter of the tumor on the pretreatment MRI The tumor volume showing 18F-BPA PET hot uptake lesions at pretreatment state 18F-BPA PET uptake avidity The relationship between H3K27-altered status and prognosis The prediction rate of progression of DMG or DSG using 11C-MET-PET hot uptake lesions or 18F-BPA PET hot uptake lesions The differences between tumor volume showing 18F-BPA PET hot uptake lesions and the progressive lesions on MRI The evaluation of the property between 18F-BPA PET and 11C-MET PET	—

Measure

Time frame

Overall Survival Progression free survival The status of H3K27-altered in Immunohistochemical staining of the surgical specimens RIng-like enhancement or T2WI high intensity lesions The maximal diameter of the tumor on the pretreatment MRI The tumor volume showing 18F-BPA PET hot uptake lesions at pretreatment state 18F-BPA PET uptake avidity The relationship between H3K27-altered status and prognosis The prediction rate of progression of DMG or DSG using 11C-MET-PET hot uptake lesions or 18F-BPA PET hot uptake lesions The differences between tumor volume showing 18F-BPA PET hot uptake lesions and the progressive lesions on MRI The evaluation of the property between 18F-BPA PET and 11C-MET PET

—

Contacts

Public ContactTakao Tsurubuchi

University of Tsukuba Hospital

t-tsurubuchi@md.tsukuba.ac.jp+81-29-853-3220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026